Neoadjuvant Pegylated Lipsomal Doxorubicin/Cyclophosphamide Plus Trastuzumab/Pertuzumab Yields Promising Efficacy in HER2+ Breast Cancer

Article

Findings from a phase 2 clinical study indicated that neoadjuvant pegylated liposomal doxorubicin plus cyclophosphamide, trastuzumab, and pertuzumab demonstrated promising efficacy and safety in the treatment of HER2-positive breast cancer.

Treatment with a neoadjuvant combination of pegylated liposomal doxorubicin plus cyclophosphamide, trastuzumab (Herceptin), pertuzumab (Perjeta), and a taxane could be a safe and effective treatment option for patients with HER2-positive breast cancer, according to preliminary results from a single-arm phase 2 study that were presented at the 2022 European Society for Medical Oncology (ESMO) Congress.


Among patients who received the combination, the pathologic complete response (pCR) rate was 59.4% (n = 38/64). Moreover, the overall response rate (ORR) after the first four cycles of treatment was 68.8%.

In this trial, a total of 78 patients enrolled, of whom 64 had pathological results. Eligible patients had been diagnosed with non-metastatic HER2-positive breast cancer and needed to have a tumor measuring 2 cm or greater or have positive lymph nodes. Patients also needed to have a left ventricular ejection fraction (LVEF) of 55% or more.

Neoadjuvant treatment consisted of pegylated liposomal doxorubicin at a dose of 30 to 35 mg/m2 plus cyclophosphamide, trastuzumab, and pertuzumab every 3 weeks for 4 cvcles followed by a taxane and trastuzumab plus pertuzumab for an additional 4 cvcles.

The primary end point was pCR rate, and ORR after the first 4 cycles of treatment served as the secondary end point.

In total, 29.7% of patients were aged 40 years and younger and 70.3% were over 40 years of age. Over half of all patients had hormone receptor (HR)–positive disease (54.7%). In total, 62.5% of patients had T1 to T2 tumor staging and 37.5% were T3 to T4. Most patients had at least 1 positive lymph node (62.5%) and the majority had stage II disease (71.9%).

In a subgroup analysis, patients aged 40 years or younger experienced a pCR rate of 42.1%, and those who were older than 40 had a pCR of 66.7%. Patients whose disease was HR negative, the pCR rate was 65.5% (19/29) compared with 54.3% in the HR-positive population. In patients with T1 to T2 tumor staging, the pCR rate was 57.5% vs 62.5% among those with T3 to T4 staging. Moreover, those who were lymph node–negative experienced a pCR rate of 70.6% vs 55.3% in the lymph node–positive group. Additionally, patients with clinical stage II disease experienced a pCR rate of 56.5%, and for those with stage III disease, the rate was 66.7%.

In terms of safety, the most common grade 3/4 adverse effects (AEs) included white blood cell count decrease (21.9%), lymphocyte count decrease (21.9%), and neutrophil count decrease (18.8%). Additionally, 6 patients experienced asymptomatic LVEF decline by 10% or more from baseline; notably, all LVEFs were above 55%.


Reference


Yang Y, Jin L, Rao N, et al. 192P: A phase I single-arm clinical study of neoadjuvant treatment with pegylated liposomal doxorubicin (PLD) plus cvclophosphamide (C) combined with trastuzumab (H) and pertuzumab (P) in HER2-positive (HER2+) breast cancer (BC). Ann Oncol. 2022;33(suppl 7):S55-S84. doi:10.1016/annonc/annonc1038

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content